Status:
COMPLETED
Lactoferrin Treatment in HIV Patients
Lead Sponsor:
Jason Baker
Collaborating Sponsors:
Ventria Bioscience
Conditions:
HIV Infection
Eligibility:
All Genders
40+ years
Phase:
PHASE2
Brief Summary
Our general goal is to evaluate the potential effectiveness of recombinant lactoferrin (1500mg bid) for reducing inflammation among HIV positive participants.
Eligibility Criteria
Inclusion
- HIV-positive participants receiving Antiretroviral Therapy (ART) for \>1 year
- HIV RNA level \<200 copies/mL for at least 6 months (≥2 separate values)
- Age \>40 years
Exclusion
- Prior cardiovascular disease or stroke
- Diabetes
- Rheumatologic Diseases
- Pregnancy
- Chronic kidney disease, stage IV or V (creatinine clearance \<30 mL/min/1.73m2)
- Cirrhosis or end-stage liver disease
Key Trial Info
Start Date :
September 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2018
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT01830595
Start Date
September 1 2014
End Date
January 1 2018
Last Update
December 31 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hennepin County Medical Center
Minneapolis, Minnesota, United States, 55415